153 related articles for article (PubMed ID: 35290169)
1. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
Criner GJ; Lang FM; Gottlieb RL; Mathews KS; Wang TS; Rice TW; Madduri D; Bellam S; Jeanfreau R; Case AH; Glassberg MK; Lyon GM; Ahmad K; Mendelson R; DiMaio JM; Tran MP; Spak CW; Abbasi JA; Davis SG; Ghamande S; Shen S; Sherman L; Lowry S
Am J Respir Crit Care Med; 2022 Jun; 205(11):1290-1299. PubMed ID: 35290169
[No Abstract] [Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
Bonaventura A; Vecchié A; Wang TS; Lee E; Cremer PC; Carey B; Rajendram P; Hudock KM; Korbee L; Van Tassell BW; Dagna L; Abbate A
Front Immunol; 2020; 11():1625. PubMed ID: 32719685
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
7. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Temesgen Z; Burger CD; Baker J; Polk C; Libertin CR; Kelley CF; Marconi VC; Orenstein R; Catterson VM; Aronstein WS; Durrant C; Chappell D; Ahmed O; Chappell G; Badley AD;
Lancet Respir Med; 2022 Mar; 10(3):237-246. PubMed ID: 34863332
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury.
Paine R; Standiford TJ; Dechert RE; Moss M; Martin GS; Rosenberg AL; Thannickal VJ; Burnham EL; Brown MB; Hyzy RC
Crit Care Med; 2012 Jan; 40(1):90-7. PubMed ID: 21926600
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp KA; Gooderham M; Jenkins R; Vender R; Szepietowski JC; Wagner T; Hunt B; Souberbielle B;
Br J Dermatol; 2019 Jun; 180(6):1352-1360. PubMed ID: 30207587
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
12. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Patel J; Bass D; Beishuizen A; Bocca Ruiz X; Boughanmi H; Cahn A; Colombo H; Criner GJ; Davy K; de-Miguel-Díez J; Doreski PA; Fernandes S; François B; Gupta A; Hanrott K; Hatlen T; Inman D; Isaacs JD; Jarvis E; Kostina N; Kropotina T; Lacherade JC; Lakshminarayanan D; Martinez-Ayala P; McEvoy C; Meziani F; Monchi M; Mukherjee S; Muñoz-Bermúdez R; Neisen J; O'Shea C; Plantefeve G; Schifano L; Schwab LE; Shahid Z; Shirano M; Smith JE; Sprinz E; Summers C; Terzi N; Tidswell MA; Trefilova Y; Williamson R; Wyncoll D; Layton M
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36229048
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
[TBL] [Abstract][Full Text] [Related]
14. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
16. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Temesgen Z; Assi M; Shweta FNU; Vergidis P; Rizza SA; Bauer PR; Pickering BW; Razonable RR; Libertin CR; Burger CD; Orenstein R; Vargas HE; Palraj R; Dababneh AS; Chappell G; Chappell D; Ahmed O; Sakemura R; Durrant C; Kenderian SS; Badley AD
Mayo Clin Proc; 2020 Nov; 95(11):2382-2394. PubMed ID: 33153629
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
Am J Respir Crit Care Med; 2022 Sep; 206(6):801. PubMed ID: 36112778
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
19. Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.
Shimasaki S; Baba T; Ogura T; Akasaka K; Matsushima H; Izumi S; Takasaki J; Tsushima K; Kinouchi T; Kichikawa Y; Awashima M; Izumo T; Awano N; Nishimura N; Tazawa R; Mikami A; Kitamura N; Ishii H; Kurihara Y; Taniguchi M; Aikawa S; Okada M; Morita Y; Ishikawa Y; Ohinata A; Nakata K
Infect Dis (Lond); 2023 Dec; 55(12):857-873. PubMed ID: 37729076
[TBL] [Abstract][Full Text] [Related]
20. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
Caricchio R; Abbate A; Gordeev I; Meng J; Hsue PY; Neogi T; Arduino R; Fomina D; Bogdanov R; Stepanenko T; Ruiz-Seco P; Gónzalez-García A; Chen Y; Li Y; Whelan S; Noviello S;
JAMA; 2021 Jul; 326(3):230-239. PubMed ID: 34283183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
